Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700029120

Trial Profile

Clinical Trials Insight: 700029120

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2010

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 14 Oct 2010 According to an Almirall media release, results from 3 pivotal clinical studies of tetrahydrocannabinol/cannabidiol (Sativex) were presented in a satellite symposium at the 26th annual congress of the ECTRIMS.
    • 12 Sep 2009 Results presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
    • 09 Sep 2009 Primary endpoint 'Improvement in symptoms' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top